MedPage Today on MSN
Better Survival in Refractory CRC With Chemo Plus Bevacizumab, Real-World Study Says
OS of 8.9 months versus 5.8 months with trifluridine/tipiracil alone, supporting phase III ...
A phase 1 dose-escalation study of GCC19CART: A novel CAR T-cell therapy for metastatic colorectal cancer in the United States. Obesity (BMI ≥ 30) 7.9% (406) 14.0% (714) 0.53 [0.47 - 0.60] Propensity ...
Major pathologic response and long-term clinical benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after neoadjuvant chemotherapy. This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results